Dilated Cardiomyopathy Epidemiology Forecast Through 2034

DelveInsight's "Dilated Cardiomyopathy - Epidemiology Forecast - 2034" report delivers an in-depth understanding of dilated cardiomyopathy, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the Dilated Cardiomyopathy epidemiology outlook, patient pool segmentation, disease burden, and forecasted trends, Click here: Dilated Cardiomyopathy Epidemiology Forecast http://www.delveinsight.com/report-store/dilated-cardiomyopathy-dcm-epidemiology-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the Dilated Cardiomyopathy Epidemiology Report:
• According to DelveInsight's estimates, the total prevalent cases of dilated cardiomyopathy in the 7MM were approximately 3,045,174 in 2023, and are expected to increase by 2034.
• Among the 7MM, the US accounted for approximately 51.8% of total diagnosed prevalent cases of dilated cardiomyopathy in 2023, followed by EU4 and the UK at nearly 37.6%, and Japan at around 10.6%. These figures are expected to change by 2034.
• Among EU4 and the UK in 2023, Germany recorded the highest diagnosed prevalent population with nearly 103,096 cases, followed by France with approximately 83,529 cases. Spain had the lowest diagnosed prevalent population with nearly 57,806 cases.
• The diagnosed prevalent cases of dilated cardiomyopathy varied by gender, with males exhibiting significantly higher prevalence than females. In 2023, overall prevalence in males across the 7MM was approximately 732,232 cases vs. 338,279 cases in females.
• In the US specifically, gender-specific cases in 2023 were nearly 351,075 for males and 203,312 for females, with both figures expected to rise during the forecast period.
• Japan accounted for the second-highest diagnosed prevalent cases of dilated cardiomyopathy among the 7MM, with approximately 113,585 cases in 2023. Of these, nearly 34,076 were genetic or familial cases, while approximately 79,510 were non-familial or other dilated cardiomyopathy cases.
• Dilated cardiomyopathy is the most common type of cardiomyopathy, typically affecting individuals aged 20-60, and is characterized by progressive enlargement of the heart's left ventricle leading to decreased pumping function and heart failure.
• While the cause is often idiopathic, roughly half of cases are inherited or familial. Acquired causes include viral myocarditis, alcohol abuse, chemotherapeutic agents, autoimmune diseases, and nutritional deficiencies.
• The epidemiology report covers total prevalent cases, diagnosed prevalent cases, gender-specific cases, and familial vs. non-familial cases across the 7MM from 2021 to 2034.
• The Dilated Cardiomyopathy Epidemiology Forecast report is expected to reflect an upward trajectory driven by aging populations, improving diagnosis rates, and greater clinical recognition of both familial and non-familial cases across the 7MM.

Dilated Cardiomyopathy Overview
Dilated cardiomyopathy (DCM) is a progressive heart condition characterized by enlargement of the heart's left ventricle, leading to decreased pumping function and heart failure. According to the National Organization for Rare Disorders (NORD), patients have systolic dysfunction and may or may not have overt symptoms of heart failure. It is the most common type of cardiomyopathy and typically affects those aged 20-60.
DCM can be classified as either primary or secondary. Symptoms range from asymptomatic to severe heart failure, including dyspnea on exertion, fatigue, palpitations, peripheral edema, and arrhythmias such as ventricular tachycardia and atrial fibrillation. Complex interactions between genetic predisposition, environmental factors, and molecular mechanisms can contribute to mitochondrial dysfunction, myocardial damage and remodeling, and hemodynamic consequences.

Get a Free Sample for the Dilated Cardiomyopathy Epidemiology Report http://www.delveinsight.com/report-store/dilated-cardiomyopathy-dcm-epidemiology-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Dilated Cardiomyopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2021 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dilated Cardiomyopathy Epidemiology Segmentation:
The Dilated Cardiomyopathy epidemiology report proffers epidemiological analysis for the study period 2021-2034 in the 7MM segmented into:
• Total Prevalent Cases of Dilated Cardiomyopathy
• Total Diagnosed Prevalent Cases of Dilated Cardiomyopathy
• Gender-Specific Cases of Dilated Cardiomyopathy
• Familial and Non-Familial Cases of Dilated Cardiomyopathy

Download the report to understand which factors are driving Dilated Cardiomyopathy epidemiology trends @ http://www.delveinsight.com/report-store/dilated-cardiomyopathy-dcm-epidemiology-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Dilated Cardiomyopathy Diagnosis and Disease Burden
The diagnosis of dilated cardiomyopathy involves a systematic approach aimed at identifying structural and functional abnormalities in the heart and ruling out other potential causes of cardiac dysfunction. DCM is diagnosed through a comprehensive evaluation that includes a combination of clinical assessment, imaging studies, laboratory tests, and genetic testing.
The report assesses the disease risk and burden of dilated cardiomyopathy across the 7MM, providing detailed growth opportunity insights by patient population segmentation. The epidemiology models developed by DelveInsight's Masters and PhD-level epidemiologists are interactive, dashboard-enabled, and built on transparent and consistent methodologies.

Explore detailed insights into market forecast, emerging therapies, market trends, and key players shaping the Dilated Cardiomyopathy landscape - Dilated Cardiomyopathy Market https://www.delveinsight.com/report-store/dilated-cardiomyopathy-dcm-epidemiology-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Dilated Cardiomyopathy Epidemiology Drivers
• Aging global population and rising incidence of cardiac conditions
• Increasing recognition of familial/genetic forms driving diagnosis rates
• Improved clinical awareness and expanded use of imaging-based diagnostic tools
• Advances in genetic testing identifying hereditary DCM cases earlier
• Growing patient pool due to rising prevalence of acquired triggers (viral infections, alcohol use, chemotherapy exposure)

Dilated Cardiomyopathy Epidemiology Barriers
• Underdiagnosis driven by asymptomatic early-stage presentation
• Limited access to genetic testing and advanced cardiac imaging in certain geographies
• Overlap of DCM symptoms with other cardiac conditions complicating early differentiation

Scope of the Dilated Cardiomyopathy Epidemiology Report
• Study Period: 2021-2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Epidemiology Segmentation: Total prevalent cases, total diagnosed prevalent cases, gender-specific cases, familial and non-familial cases of dilated cardiomyopathy
• Disease Risk and Burden Assessment across all 7MM geographies
• 11-Year Forecast of dilated cardiomyopathy patient pool through 2034
• Key Questions Addressed: Historical and forecasted patient pool, CAGR of patient population growth, country-level diagnosed prevalent population, growth opportunities by geography

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Contact No.: +14699457679
Address: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.